Technology Insight: transcoronary ablation of septal hypertrophy
Haran Burri and Ulrich Sigwart*
Correspondence *Cardiology Service, University Hospital, 1211 Geneva 14, Switzerland
Email ulrich.sigwart@hcuge.ch
Outflow tract obstruction affects 5-10% of hypertrophic cardiomyopathy patients. Although myectomy is the gold standard treatment, alcohol septal ablation has emerged as an alternative nonsurgical procedure. Burri and Sigwart present a round up of the past 10 years' experience and discuss the pros and cons of this procedure.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
